Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWilmington Regulatory News (WIL)

Share Price Information for Wilmington (WIL)

Share Price is delayed by 15 minutes
Get Live Data
260.00    0.00 (0.00%)
Bid:
252.00
Ask:
257.00
Spread: 5.00 (1.984%)
Market Cap: £232.84m
WIL Live PriceLast checked at - London Stock Exchange

Intraday Wilmington Share Chart

Trading Statement

18 May 2017 07:00

RNS Number : 4771F
Wilmington PLC
18 May 2017
 

18 May 2017

 

Wilmington plc

Q3 Trading Update

 

Wilmington plc ("Wilmington" or "the business") the provider of information, education and networking services in Risk & Compliance, Professional, and Healthcare knowledge areas is today providing a trading update for the nine-month period to 31 March 2017.

 

Trading Update

Group revenue was up 13% (up 8% in constant currency) during the nine months ended 31 March 2017. Overall, revenue is in line with expectations, with good organic growth coming from our core growth areas of Risk & Compliance and the Healthcare businesses. Revenue growth was further supported by good contributions from the acquisitions made over the last two years and from the beneficial impact of currency translation. Offsetting this growth was, as previously reported, declines in some areas of the Professional division and the legacy charities and data suppression businesses.

During the nine-month period, Wilmington continued to see growth in reported operating profits, although this profit growth has been partially offset as reported in the interim results by continued investment across the business particularly in the US and in the compliance training areas where we see significant scope for stronger growth in the medium term.

 

Operational Review

Risk & Compliance 

Risk & Compliance again delivered strong revenue growth up 11% driven mainly by compliance training. In support of this growth and as reported in the interim results, we have continued to invest in new products, in the new North American operation and in additional support staff to expand our infrastructure and drive ICA membership. We have also been successful recently in winning two large international training programs which will benefit the business over the summer and we have brought in additional resources accordingly. This additional resource has further impacted margins in the short term but is expected to benefit contribution in 2017/18. Further investment continues to be made in our new North American compliance training business and in Compliance Week to expand its geographical reach in terms of events and information coverage.

Professional

Revenue was up 5% benefitting from favourable currency translation and the strong maiden performance from SWAT as well as our other accountancy training operations. However, the division continues to see the impact of the challenging conditions within the legal market as well as the impact of the weaker start to the financial year for AMT albeit we have recently regained stability in the Asia Pacific market.

The process for the planned disposal of Ark is underway and negotiations continue with potential buyers. Whilst Project Sixth Gear will provide benefits to the whole group, much of the work is centred around integrating the training businesses making up the bulk of the Professional division. This initiative is progressing well and we are attracting high calibre applicants for the divisional head role.

Healthcare 

Revenue was up 23% driven by organic growth across the board from our healthcare businesses and acquisitions made over the last two years. This was partially offset by continued declines in our legacy non-healthcare data suppression and charities businesses which make up around 20% of the division. HSJ, acquired on 31 January 2017 has also performed well and the HSJ team has been transferred to our Underwood Street premises. Integration is progressing on plan and is expected to be largely completed by the end of our 2016/17 financial year.

Cash Flow

Net debt as at 31 March 2017 was £51.4m (2016: £34.5m). This reflects strong cash generation and includes £20.3m paid in cash for two acquisitions made during the period. The Group has an overall borrowing facility of £85m which was extended from £65m in January 2017.

Adjusted measures

Effective from 30 June 2017 Wilmington will include share based payments costs within its definition of adjusted results. Share based payment costs amounted to £0.6m in 2015/16 and are not expected to be materially different during 2016/17.

Outlook

Wilmington continues to see the trends of tighter regulatory control and more complex legislation being implemented in most of our key markets, which in turn is driving demand for many of our products and services. We have and will continue to invest in our Compliance business to provide the infrastructure and support for anticipated future growth.

Despite the continued investment in infrastructure, the financial performance is in line with the Board's expectations and Wilmington is on track to deliver against expectations for the full year.

The information communicated in this announcement is inside information for the purposes of Article 7 of Market Abuse Regulation No. 596/2014

 

-End-

 

For further information, please contact:

Wilmington plc

Pedro Ros, Chief Executive Officer

Tony Foye, Chief Financial Officer

 

FTI Consulting

Charles Palmer / Emma Appleton / Adam Davidson

 

020 7422 6800

 

 

 

020 3727 1000

Notes to Editors

 

Wilmington plc is the recognised knowledge leader and partner of choice for information, education and networking in Risk & Compliance, Professional and Healthcare areas. Capitalised at approximately £210 million, Wilmington floated on the London Stock Exchange in 1995.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUBVNRBWAVAAR
Date   Source Headline
27th Sep 20132:29 pmRNSShare Awards
19th Sep 20137:00 amRNSPreliminary Results
12th Sep 20132:24 pmRNSHolding(s) in Company
3rd Sep 201310:15 amRNSTotal Voting Rights
27th Aug 20133:57 pmRNSHolding(s) in Company
16th Aug 20137:00 amRNSAcquisition of Compliance Week
5th Aug 20133:22 pmRNSTotal Voting Rights
10th Jul 201311:04 amRNSHolding(s) in Company
1st Jul 20139:59 amRNSTotal Voting Rights
27th Jun 201312:41 pmRNSNotice of Results
4th Jun 20139:45 amRNSVoting Rights and Capital
16th May 20137:00 amRNSInterim Management Statement
10th May 20133:03 pmRNSBLOCK LISTING SIX MONTHLY RETURN
1st May 201310:16 amRNSTotal Voting Rights
3rd Apr 20134:18 pmRNSVoting Rights and Capital
26th Mar 201311:04 amRNSHolding(s) in Company
15th Mar 20134:40 pmRNSSecond Price Monitoring Extn
15th Mar 20134:37 pmRNSPrice Monitoring Extension
4th Mar 20137:00 amRNSAcquisition of Inese
1st Mar 201310:56 amRNSTotal Voting Rights
26th Feb 20137:00 amRNSInterim Results
7th Feb 20133:39 pmRNSAcquisition
6th Feb 201310:41 amRNSTotal Voting Rights
4th Jan 20133:00 pmRNSNotice of Results
2nd Jan 201311:31 amRNSVoting Rights and Capital
24th Dec 201211:12 amRNSProperty Sale
21st Dec 20127:00 amRNSSegmental Analysis
18th Dec 20124:40 pmRNSSecond Price Monitoring Extn
18th Dec 20124:35 pmRNSPrice Monitoring Extension
4th Dec 20129:08 amRNSTotal Voting Rights
22nd Nov 20124:45 pmRNSHolding(s) in Company
16th Nov 20123:05 pmRNSBlocklisting Interim Review
16th Nov 20123:00 pmRNSBoard Change
16th Nov 20127:00 amRNSCapital Markets Day
14th Nov 20124:00 pmRNSResult of AGM
14th Nov 20127:00 amRNSInterim Management Statement
13th Nov 20125:00 pmRNSHolding(s) in Company
2nd Nov 20121:28 pmRNSTotal Voting Rights
29th Oct 20122:19 pmRNSDirector/PDMR Shareholding
11th Oct 20124:20 pmRNSHolding(s) in Company
11th Oct 20122:32 pmRNSHolding(s) in Company
11th Oct 201210:06 amRNSDirector/PDMR Shareholding
10th Oct 20125:30 pmRNSTreasury Shares
2nd Oct 20122:45 pmRNSVoting Rights and Capital
18th Sep 20127:00 amRNSFinal Results
3rd Sep 20123:13 pmRNSVoting Rights and Capital
17th Aug 201212:10 pmRNSHolding(s) in Company
2nd Aug 201210:31 amRNSTotal Voting Rights
24th Jul 20124:37 pmRNSHolding(s) in Company
13th Jul 20124:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.